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ABSTRACT
Fibronectin is a component of the extracellular matrix that links collagen fibers 
to integrins on the cell’s surface. The splicing isoforms, containing the ED-B domain, 
are not expressed in adult tissues but only in tumor stroma or during embryonic 
development. Fibroblasts and endothelial cells express ED-B fibronectin during 
angiogenesis. Also cancer cells can synthetize ED-B fibronectin, but its function in 
tumor growth needs to be further elucidated.
We evaluated the expression of ED-B fibronectin in prostate cancer cell lines: PC3 
and DU145. Using TGF-β, we induced epithelial to mesenchymal transition in culture 
and observed an increase of ED-B fibronectin expression. Thereafter, we evaluated 
the expression of ED-B fibronectin in multipotent mesangiogenic progenitor cells, and 
in mesenchymal stromal cells. The expression of ED-B fibronectin was much higher 
in mesenchymal than prostate cancer cells even after the epithelial to mesenchymal 
transition.
Epithelial to mesenchymal transition is a key step for tumor progression 
contributing to the metastatic spread. Therefore, circulating cancer cells could seed 
into the metastatic niche taking advantage from the ED-B fibronectin that secrete 
their own.
INTRODUCTION
Fibronectin is an essential component of the 
extracellular matrix that is necessary for the cellular 
adhesion to the stroma. Indeed, it creates a bridge 
between the molecules of the cell surface (integrins) and 
the collagen fibers [1]. Fibronectin, through the binding 
with integrins, activates intracellular pathways leading to 
cell adhesion, growth and differentiation [2]. Moreover, 
fibronectin can induce cytoskeleton modifications, 
allowing cell migration, since integrins are anchored to 
the actin fibers through the molecules talin and vinculin 
[2]. Therefore, fibronectin is necessary for embryogenesis 
and wound healing. Fibronectin is a glycoprotein that 
contains 12 fibronectin type-I repeats, 2 fibronectin 
type-II repeats, 17 fibronectin type-III repeats and a non-
homologous variable connecting segment: the IIICS. 
Two of the type III repeats can be alternatively spliced 
(ED-A and ED-B) [1]. There are at least 20 known 
different isoforms originating from a single pre-mRNA. 
The function of these isoforms remains obscure in most 
cases. ED-A and ED-B sequences are highly conserved 
among vertebrates [3] and these isoforms are abundantly 
expressed during embryogenesis supporting their role in 
vascular development, cell migration, and differentiation 
[4, 5]. In adults, ED-A and ED-B fibronectin expression 
is induced in specific conditions such as tissue repair, 
fibrosis, angiogenesis, and cell migration [4, 6]. Indeed, 
ED-B fibronectin has a restricted pattern of expression: 
it is almost undetectable in normal adult tissues and in 
mature blood vessels, but is abundant in regenerating 
tissues and around newly formed blood vessels [7, 8]. 
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Mice lacking ED-A or ED-B domain grow-up without 
obvious defects [9]. Whereas, the simultaneous knock-
out of both ED-A and ED-B exons determines embryonic 
lethality, with an incomplete penetrance, for the presence 
of multiple cardiovascular defects [9].
For their role in tissue remodeling, angiogenesis and 
migration, ED-A and ED-B isoforms could play a relevant 
role in cancer growth. Indeed, during the formation of 
metastasis, cancer cells have to seed in the metastatic niche 
through the binding of their membrane integrins with the 
fibronectin present in the extracellular matrix [10].
However, the exact role of ED-A and ED-B 
fibronectin in cancer remains largely obscure. ED-B 
fibronectin is expressed in tumor tissue [11], in particular 
in breast carcinoma [12], brain tumors [13], lymphoma 
[14] and prostate cancer [15]. High ED-B fibronectin 
expression was found around newly formed blood vessels 
and therefore could be a candidate target to treat tumor 
angiogenesis.
Accumulating evidences have shown that the 
Epithelial-Mesenchymal Transition (EMT) is necessary 
for cancer progression; especially for the metastatic spread 
[16–20]. During EMT, cells enhance the expression of 
mesenchymal markers together with the repression of 
epithelial molecules. Since fibronectin is a mesenchymal 
marker, we evaluated the expression of ED-B fibronectin 
during EMT in two prostate cancer cell lines.
RESULTS
TGF-β induces EMT in prostate cancer cell lines
EMT was induced, using TGF-β, in two cell 
lines of prostate cancer: PC3 and Du145. After 2 
weeks of TGF-β treatment, cells with an epithelial-like 
morphology acquired a more elongated shape resembling 
that of fibroblast in culture: a typical characteristic of 
mesenchymal-cells (Figure 1).
Using flow cytometry, we observed a reduction 
in the expression of the epithelial markers EPCAM 
and E-Cadherin in PC3 and Du145 cells after treatment 
with TGF-β for either 72 hours or 2 weeks.Du145 cells 
expressing E-Cadherin were 30.6% (standard deviation 
(SD)±3.4) and 78.8%(SD±1.7) after 2 weeks of culture 
with or without TGF-β, respectively (Figure 2A). A 
milder effect was observed for Du145 cells expressing 
EPCAM that were 86.2%(SD±2.3) and 99.9%(SD±0.5) 
after 2 weeks of culture with or without TGF-β, 
respectively (Figure 2A). In line with previous reports 
[21, 22], there were not differences in the percentage 
of N-Cadherin expressing cells with or without TGF-β 
treatment (after 72h and 2-week incubation) (Figure 2A). 
PC3 cells expressing EPCAM were 40.8% (SD±2.6) 
and 90.4%(SD±1.2) after 2 weeks of culture with or 
without TGF-β, respectively (Figure 2B). A milder effect 
was observed for PC3 expressing E-Cadherin that were 
97.0%(SD±3.7) and 95.6%(SD±3.4) after 2 weeks of 
culture with or without TGF-β, respectively (Figure 2A). 
There were not differences in the percentage of PC3 cells 
expressing N-Cadherin with or without TGF-β treatment 
after 72h and 2-week (Figure 2B).
Gene expression was evaluated by RT-PCR after 
2-week of TGF-β treatment. In Du145 cells, TGF-β 
significantly reduced the expression of EPCAM (-70%; 
p=0.010) and E-Cadherin (-77%; p=0.023) compared to 
controls (Figure 2C). DU145 did not express N-Cadherin 
either with or without TGF-β treatment. TGF-β did not 
induce a significant difference in vimentin expression in 
DU145 (-28%; p=0.57). In PC3 cells, TGF-β significantly 
reduced the expression of EPCAM (-70%; p=0.007) and 
Figure 1: Morphology of Du145 cells treated with or without TGF-β. After 2 weeks of treatment cells showed an elongated 
mesenchymal-like appearance. Pictures were taken by phase contrast microscopy.
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E-Cadherin (-66%; p=0.003) compared to controls (Figure 
2D). TGF-β induced a significant increase of N-Cadherin 
expression in PC3 cells (+35%; p<0.001) but not significant 
differences in vimentin expression (+4%; p=0.522).
In Du145 and PC3, western blots demonstrated a 
decrease of EPCAM and E-Cadherin expression and an 
increase of Vimentin both after 72h and 2-weeks (Figure 
2E, 2F). Western blots definitely demonstrated EMT 
Figure 2: Analysis of EMT markers: cytofluorimetric analysis of Du145 A. and PC3 B. Gene expression of EMT markers 
after 2 weeks of treatment with or without TGF-ß in DU145 C. and PC3 D. Western blot analysis of EMT markers in Du145 E. 
and PC3 F. cells after TGF-β treatment for 72h and 2 weeks. Protein lysates of U87 (human glioblastoma cell line), A549 (human lung 
adenocarcinoma cell line) and A375 (human melanoma cell line) were used as positive or negative controls.
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showing the expected EPCAM and E-cadherin signal 
reduction alongside with vimentin increase.
ED-B fibronectin expression in EMT and 
mesenchymal cells
TGF-β induced the expression of ED-B fibronectin. 
In DU145 cells, ED-B fibronectin expression was 
increased by 60% (p=0.007) after 72 h and by 73% 
(p=0.071) after 2 weeks of TGF- β treatment. In PC3 
cells, ED-B fibronectin expression was increased by 29% 
(p=0.087) after 72h and significantly by 40% (p=0.012) 
after 2 weeks of TGF-β treatment (Figure 3A). Similarly 
there was an increase of total-Fibronectin with TGF-β 
(72h and 3w) in DU145 and in PC3 after 72h of treatment 
(data not shown).
The ED-B fibronectin expression in DU145 was 
much lower than in MSCs and MPCs (Figure 3B). Even 
Figure 3: Fibronectin ED-B mRNA expression in Du145 and PC3 cell lines after 72h and 2 weeks A. Fibronectin ED-B 
expression in MPC, P2-MSC and Du145 treated for 2 weeks B.
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if the EMT was induced, the transformed PC3 and Du145 
did not show a prototypical mesenchymal phenotype such 
as MSC (EPCAMnegCD105+CD90+STRO-1+) or MPC (EP
CAMnegCD105negCD90negCD31+).
DISCUSSION
ED-B fibronectin expression increased during EMT. 
However, ED-B fibronectin expression was much higher 
in mesenchymal cells and their progenitor MPC compared 
to that of tumor cell lines undergoing EMT under the 
induction of TGF- β.
Interestingly, we observed the expression of ED-B 
fibronectin in prostate cancer cells. Fibronectin is a 
mesenchymal marker and increases in TGF-β–induced 
EMT [20, 23]. ED-B fibronectin was up regulated during 
EMT in Du145 and PC3 cells upon TGF-β induction. 
This is relevant for cancer cells’ migration and for 
their metastatic progression. Indeed, tumor cells can 
synthetize the fibronectin isoforms expressed during 
tissue remodelling and neo angiogenesis and could 
become independent from the expression of fibroblasts 
and mesenchymal cells. These two sources of ED-B 
fibronectin can contribute to create a permissive soil for 
the invasion, attachment and growth of metastases.
Physiologically, ED-B fibronectin is synthesized, 
secreted, and deposited into the extracellular matrix by 
numerous cell types such as endothelial cells of newly 
formed blood vessels and myofibroblasts [14, 24, 25]. 
Cells transformed in vitro using SV40 start to express 
ED-B fibronectin [26]. Moreover, fibronectin and ED-B 
mRNA transcripts are expressed in cancer cell lines 
including colorectal and breast carcinoma, among others 
[24]. The protein can not be described on the surface of 
these cells in vitro, probably because it is rapidly secreted. 
Indeed, ED-B fibronectin, secreted by cancer cells, 
accumulates abundantly into mouse xenograft according 
to the BC1 antibody, which is specific for human but not 
mouse fibronectin [24]. The FDC6 antibody recognizes an 
O-glycosylated epitope on a threonine, inside the IIICS 
domain, of a fibronectin isoform expressed in cancer or 
in fetal cells/tissues, but not in normal adult cells/tissues 
[27]. Lima et al. have observed the up-regulation of this 
fibronectin isoform during EMT in prostate and lung 
adenocarcinoma cell lines [27, 28]. Moreover, authors 
demonstrated that this O-glycosylated fibronectin isoform 
promotes the EMT processes [27].
ED-B fibronectin could represent an ideal target for 
cancer therapy because it is overexpressed in tumor but not 
in normal adult tissues. ED-B fibronectin has a different 
expression in different tumors in terms of intensity and 
distribution of the staining [29]. Certain cancers express 
high level of ED-B fibronectin (i.e. lung cancer, melanoma, 
colon cancer) whereas others seem to increase the ED-B 
isoform while they acquire a more aggressive phenotype (i.e. 
lymphoma, prostate cancer, thymoma/thymic carcinoma and 
thyroid cancer). Our group has already demonstrated ED-B 
fibronectin expression in lymphomas and leukemia [14]. 
ED-B fibronectin expression was higher in the wall of blood 
vessels of high-grade compared to low-grade non-Hodgkin 
lymphomas. Similarly, ED-B fibronectin was expressed 
in perivascular spaces of bone marrow samples with 
lymphoma or leukemia infiltration, whereas perivascular 
spaces of normal bone marrow were almost negative 
[14]. Low-grade prostate cancers presented a lower ED-B 
fibronectin expression than undifferentiated ones, indicating 
a correlation between the grade of differentiation and ED-B 
fibronectin expression. Therefore, we have chosen for these 
experiments PC3 and DU145: two cell lines derived from 
metastatic tumors that have lost their androgen dependency 
typical of the more differentiated prostate cancers. Anti-
ED-B radiolabeled immunoconjugates have demonstrated 
in vivo the presence of ED-B fibronectin in tumor stroma 
of lymphomas and carcinomas including lung and prostate 
[14]. Therefore, the use of anti-ED-B radiolabeled immune-
conjugates represents a promising approach to target 
cancer progression. The treatment of advanced tumors with 
131I-L19 SIP direct against ED-B fibronectin is associated 
with thrombocytopenia of grade 3-4 [30]. Our observation 
of high ED-B fibronectin expression in bone marrow 
mesenchymal precursors (MSC and MPC) could contribute 
to explain this side effect.
MPC can be isolated from bone marrow upon 
appropriate conditions [31] and thereafter differentiated 
into blood vessels, bone, cartilage and MSC [32]. Indeed, 
MSC are cells already committed through differentiation 
compared to MPC. Interestingly, MSC expressed a much 
higher degree of ED-B fibronectin that MPC. Therefore, 
we believe that ED-B fibronectin is a marker of EMT and 
possibly an interesting target for therapy in more advanced 
tumors.
MATERIALS AND METHODS
Cell culture and TGF-β treatment
Human prostate cancer cell lines PC3 and Du145 
were purchased from the American Type Culture 
Collection (ATCC, Manassas, VA, USA). PC3 and Du145 
were cultured respectively in RPMI/F12 1:1 mixture 
(Life Technologies, Carlsbad, CA, USA) and RPMI 1640 
medium (Life Technologies) supplemented with 10% 
foetal bovine serum (FBS, Sigma-Aldrich, St. Louis, MO, 
USA), 2mM L-glutamine (Lonza, Wolkersville, MD, 
USA), 100IU/ml penicillin (Pharmacia & Upjohn S.p.A., 
Milan, Italy), 100IU/ml streptomycin (Bristol-Myers 
Squibb S.p.A., Sermoneta, Italy). Cells were cultured 
at 37°C in 5% CO
2
 incubator. In order to induce EMT, 
cell lines were treated with 20 ng/ml TGF-β (Miltenyi 
Biotech, Bergisch Gladbach, Germany) for six passages 
(2 weeks). Cell detachment has been performed using 
0.05%trypsin-0.02%ethylenediaminotetraacetic acid (Life 
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Technologies). The experiments have been performed in 
triplicate.
Immunophenotypic analysis
TGF-β untreated and treated cells were analyzed 
after 72h incubation and at the end of the experiment (6 
passageses-2 weeks). The cells were detached and a total 
of 100 μl of cell suspension (5×105cells) was aliquot per 
tube. The labelled monoclonal antibodies (mAbs) were 
incubated for 30 min at 4°C and thereafter samples were 
washed twice in MACSQuant running buffer (Miltenyi 
Biotech, Bergisch Gladbach, Germany). The flow 
cytometer was set using cells stained with isotype controls. 
Cells were gated on a forward versus side scatter plot to 
eliminate debris. Acquisition was performed using 10,000 
cells that were analyzed by MACSQuant cytofluorimeter 
running the MACSQuantify software (Miltenyi Biotech). 
Cells were stained using mAbs specific for: EPCAM-
APC (Miltenyi Biotech), E-cadherin-PE and N-cadherin-
PE (Abcam, Cambridge, UK), CD44-FITC (Miltenyi 
Biotech), CD105-PE-Vio770 (Miltenyi Biotech), CD90-
FITC (Miltenyi Biotech), STRO-1 Alexafluor 647 
(Biolegend, San Diego, CA), CD31-PE/Cy7 (Miltenyi 
Biotech).
Western blot
Cells were lysed on ice using RIPA Lysis buffer kit 
with protease inhibitor cocktail (Santa Cruz Biotechnology 
Inc., Heidelberg, Germany). Protein concentration was 
measured using a BCA protein assay kit (Pierce, Thermo 
Scientific, Rockford, U.S.A). Thirty μg of reduced 
proteins in Laemmli sample buffer (Biorad, Segrate, 
Milan, Italy) were resolved using Gel precast Miniprotean 
4-20% (Biorad) and transferred to nitrocellulose by Semi-
Dry Trans-Blot Turbo System (Biorad). Membranes were 
blocked with 5% non-fat dry milk (Biorad) in TBS-T, and 
incubated with primary antibody overnight at 4°C and 
thereafter with the appropriate HRP-conjugated secondary 
antibody (Biorad) for 1h at room temperature. Membranes 
were developed using ECL detection reagent (Amersham, 
Glattbrugg, Switzerland). The primary antibodies were: 
anti-EP-CAM, anti-E-cadherin, anti-Vimentin (1:1000) 
and anti-α-Tubulin (1:2000) (Cell Signalling Technology, 
Massachusetts, USA). Blots were stripped for 20 minutes 
using the stripping buffer (Thermo Scientific) before re-
probing.
Quantitative RT-PCR
RNA extraction was performed using RNeasy 
Mini Kit (Qiagen GmbH, Hilden, Germany), according 
to the manufacturer protocol. One microgram of each 
RNA sample was retrotranscribed by QuantiTect Reverse 
Transcription Kit (Qiagen GmbH) and 30-fold dilutions 
of cDNAs were analyzed by Quantitative RT-PCR on 
iCycler-iQ5 Optical System (Bio-Rad Laboratories, 
Hercules, CA), using SsoAdvanced SYBR Green 
SuperMix (Bio-Rad). All samples were run in duplicate. 
Primers were designed from coding sequences published 
on Gene Bank database with the help of Beacon Designer 
v.7 Software (Premier Biosoft International, Palo Alto, 
CA, USA); sequences are available upon request. Relative 
quantitative analysis was performed following 2-ΔΔCt 
Livak’s method [33]. Normalization of PC3 data was 
performed with B2M and ATP5B. In Du145 expression 
analysis, four housekeeping genes (ACTB, ATP5B, 
GAPDH, HPRT) were chosen for normalization on the 
basis of the GeNorm study.
Bone marrow-derived multipotent stromal cell 
cultures
Bone marrow samples were obtained from 10 
patients (6M/4F, median age 69 years) undergoing 
orthopaedic surgery. Mesangiogenic progenitor cells 
(MPCs) were isolated from bone marrow mononuclear 
cells (BM-MNCs) cultured in DMEM with 10% pooled 
human AB serum, obtained from male donors only 
(PhABS, Lonza, Walkersville MD-USA), as previously 
described [34]. Mesenchymal stromal cell (MSC) cultures 
were obtained differentiating MPC in MesenPRO-
RS ® medium (Invitrogen, Carlsband CA-USA) for two 
passages (P2-MSC) [31].
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